A Pituitary Mass That Isn't a Tumor: Steroids or a Closer Look First
A single patient, six weeks postpartum, with new headache, mild visual symptoms, and a pituitary mass that could be lymphocytic hypophysitis, IgG4-related disease, or an entirely unrelated nonfunctioning adenoma. The disagreement is whether to treat empirically or push for tissue first.
B.C., a 29-year-old woman, is six weeks postpartum with her first child, a fact that turns out to be clinically load-bearing rather than incidental, since lymphocytic hypophysitis has a well-documented association with late pregnancy and the peripartum period specifically. What brought her in was a headache that has been building for two weeks, distinct from ordinary new-parent exhaustion, along with mild peripheral vision changes she noticed only because a family member walked into a room from her left side without her registering it the way she normally would. Pituitary MRI showed a 14mm sellar mass with symmetric, homogeneous enlargement and thickening of the pituitary stalk — a pattern that favors an inflammatory process like hypophysitis over a typical adenoma, which more often grows eccentrically rather than symmetrically, though imaging alone cannot fully distinguish the two, nor reliably distinguish ordinary lymphocytic hypophysitis from the rarer IgG4-related variant, which can involve other organs and carries different long-term management implications.
Her hormonal panel adds a real complication rather than resolving it: she has new central hypothyroidism and a blunted cortisol response, consistent with hypophysitis affecting multiple axes, but her prolactin is also mildly elevated, a finding that fits equally well with stalk compression from any sellar mass, inflammatory or not, disrupting the normal dopamine-mediated suppression of lactotroph function. Definitive diagnosis of lymphocytic hypophysitis, as opposed to a nonfunctioning adenoma with secondary inflammation or a true IgG4-related process, requires tissue — pituitary biopsy, typically obtained via the same transsphenoidal approach used for adenoma resection, carrying real procedural risk of its own for a diagnosis that, if inflammatory, often responds to glucocorticoids without any surgery at all. Her postpartum timing is the single detail that shifts the odds furthest toward ordinary lymphocytic disease over the rarer IgG4-related variant, since the association with late pregnancy and the peripartum period is specific to lymphocytic hypophysitis and not a recognized feature of IgG4-related pituitary involvement.
Treating the inflammation before biopsy proves it's inflammation
I'd start empiric high-dose glucocorticoid therapy now rather than wait for biopsy. Her presentation — postpartum timing, symmetric enlargement, stalk thickening, multi-axis dysfunction — fits the classic lymphocytic hypophysitis picture closely enough that treating presumptively is standard practice here, and if it's right, she can avoid surgery and biopsy risk entirely, with mass effect and hormone function both often improving on steroids alone.
I'd want a harder look at the diagnostic uncertainty before treating presumptively, specifically because of what a wrong presumption costs here. If this is actually a nonfunctioning adenoma with incidental secondary inflammation rather than primary hypophysitis, high-dose steroids won't meaningfully shrink it and we'll have delayed a more accurate diagnosis and a real treatment plan by weeks, during which her visual symptoms — mild but present now — could progress.
The pending IgG4 level matters too, not as a footnote — if this is IgG4-related hypophysitis rather than ordinary lymphocytic disease, that changes both her steroid response pattern and her need for systemic evaluation for other organ involvement, and treating empirically before that result returns risks starting the wrong long-term management plan, not just the wrong short-term one.
That's a real distinction I'd fold into the plan rather than treat as a reason to wait on biopsy alone. Start high-dose prednisone now given the strength of the clinical pattern and the real, if mild, visual symptoms that argue against delaying treatment for weeks — but hold the IgG4 result and a formal visual field exam as explicit checkpoints at 2 weeks: if she isn't responding and IgG4 comes back elevated, that combination should trigger biopsy rather than continued empiric treatment on an unconfirmed diagnosis.
Agreed: start a high-dose prednisone taper empirically given the strength of the clinical pattern, alongside physiologic hydrocortisone and levothyroxine replacement for her confirmed deficiencies. Formal visual field testing and pending IgG4 level reviewed together at 2 weeks as an explicit checkpoint — non-response combined with an elevated IgG4 result triggers biopsy; a clear response supports continuing the presumptive diagnosis and completing the taper.
Both physicians converged on this staged approach; the neurosurgeon's initial preference for biopsy-first was resolved by building a concrete, near-term trigger for escalation into the empiric-treatment plan rather than treating diagnosis and treatment as sequential, separate steps.